查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1884069

重组凝血酶市场规模、占有率、成长及全球产业分析：依类型、应用和地区划分的洞察与预测（2024-2032 年）

Recombinant Thrombin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 186 Pages | 商品交期: 请询问到货日

价格

重组凝血酶市场成长驱动因子

全球重组凝血酶市场正经历稳定成长，其成长动力主要来自外科手术数量的增加、人口老化以及安全有效的止血剂的日益普及。根据本报告，预计该市场规模将在 2024 年达到 4.398 亿美元，2025 年将增长至 4.583 亿美元，并在 2032 年达到 6.551 亿美元，预测期内复合年增长率 (CAGR) 为 5.2%。北美地区凭藉其先进的医疗保健基础设施和需要外科手术干预的慢性疾病高发生率，在 2024 年占市场主导地位，市场占有率达 42.11%。

以重组DNA技术生产的重组凝血酶与牛源或人源凝血酶相比，安全性较高，免疫原性、病毒性和过敏反应的风险显着降低。随着生物技术的进步以及医疗机构对高纯度止血剂日益重视，重组凝血酶在心臟病学、神经病学、骨科、肝病学和普通外科等专科领域的临床应用价值不断提升。

市场动态

推动因素

手术量增加

包括心血管疾病、骨科疾病和神经系统疾病在内的慢性疾病的快速增长，导致全球手术量激增。吸烟、压力和缺乏运动等生活方式风险进一步加重了疾病负担。因此，医疗机构扩大采用重组凝血酶进行精准的术中出血管理。

例如，德国预计2023年将进行168,841例心臟手术，比2022年增长4.1%，这表明对可靠的止血剂的需求不断增长。

限制因子

重组凝血酶成本高

复杂的生物技术生产流程显着增加了生产成本，使得重组凝血酶比传统凝血酶产品更昂贵。例如，20,000 IU的Recotron价格约为377.23美元，这限制了其在低收入国家和医疗资源匮乏地区的应用。此外，儘管其安全性极佳，但有限的医保报销进一步阻碍了其市场渗透。

机会

人源与牛源凝血酶的副作用创造了市场机会

传统的凝血酶产品，例如牛源凝血酶 THROMBIN-JMI，与多种不良事件相关，包括免疫反应、出血併发症和血栓栓塞。重组凝血酶消除了病原体传播的风险，并显着降低了抗体的形成。

目前，Recothrom 是唯一获得 FDA 批准的重组凝血酶产品，这为市场参与者开发新配方和扩展产品线提供了巨大的机会。

挑战

复杂的生产製程

重组凝血酶的生产需要精确的基因克隆、可控制的细胞培养系统和先进的纯化技术。批次缺陷、严格的合规要求以及可扩展性挑战推高了营运成本，阻碍了市场的快速扩张。

市场趋势

合併止血剂的研发加速

各大公司正加速研发联合产品，以增强术中止血效果。

2023年4月，百特公司推出了Flosil + Recotron，这是全球首款含有重组凝血酶的可流动止血剂，标誌着外科止血技术领域的重大突破。

市场区隔分析

依应用领域

2024年，治疗领域推动了市场成长，这主要得益于心血管外科、神经外科、骨科和肝臟外科的广泛应用。光是在美国，2024年就进行了超过一百万例经导管心血管手术，所有这些手术都需要有效的止血。

重组凝血酶在研究领域也占了相当大的占有率，这得益于其在融合蛋白裂解、分子生物学研究和高纯度实验室应用中的广泛用途。

依最终使用者划分

医院和门诊手术中心 (ASC) 因其手术量大而成为市场的主要推动力。例如，2024 年美国进行了超过 70 万例膝关节置换手术。

由于重组蛋白在生物技术研究中的应用日益广泛，研究机构也持续看到其应用范围的扩大。

区域展望

北美（2024 年市场规模：1.852 亿美元）

该地区凭藉较高的手术率、技术应用以及对安全止血剂的强烈认知，在市场中占主导地位。美国在心血管和骨科手术领域占市场领先地位。

欧洲

由于人口老化和创伤相关手术的增加，欧洲是第二大市场。德国、法国和英国在生物技术研发方面的进步也推动了市场的进一步扩张。

亚太地区

由于病患数量、手术量和研发投入的增加，预计亚太地区将实现最快的成长速度。

例如，阿斯特捷利康计划在2025年投资25亿美元在北京建立一个研发中心。

拉丁美洲、中东和非洲

成长的推动力在于医疗基础设施的改善以及微创手术中心的日益普及，例如 Burjeel Holdings 的日间手术中心，该中心于 2024 年开业。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场推动因素
  • 市场阻碍因素
  • 市场机遇
  • 市场趋势

第四章：主要发现

  • 主要国家和地区的监管环境
  • 市场技术进步
  • 主要产业趋势（併购、合作、新产品发表等）

第五章：全球重组凝血酶市场分析、洞察与预测（2019-2032）

  • 市场分析、洞察与预测 - 依应用领域划分
    • 治疗
    • 研究
  • 市场分析、洞察与预测 - 依最终用户划分
    • 医院及门诊手术中心
    • 专科诊所
    • 其他
  • 市场分析、洞察与预测 - 依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美重组凝血酶市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 美国
    • 加拿大

第七章 欧洲重组凝血酶市场分析、洞察与预测 (2019-2032)

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区重组凝血酶市场分析、洞察与预测 (2019-2032)

  • 依国家/地区
    • 中国
    • 日本
    • 印度
    • 东南亚
    • 澳大利亚
    • 亚太其他地区

第九章 拉丁美洲重组凝血酶市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章 中东与非洲重组凝血酶市场分析、洞察与预测（2019-2032）

  • 依国家划分
    • 海湾合作委员会
    • 南非
    • 其他中东和非洲国家

第十一章：竞争分析

  • 全球市占率分析（2024）
  • 公司简介
    • 百特
    • 默克集团
    • Bio-Techne
    • AMSBIO
    • Enzyme Research Laboratories Ltd.
    • Proteintech Group, Inc.
Product Code: FBI113585

Growth Factors of recombinant thrombin Market

The global recombinant thrombin market is experiencing consistent growth driven by rising surgical volumes, an aging population, and increasing adoption of safe and efficient hemostatic agents. According to the report, the market size reached USD 439.8 million in 2024, is set to grow to USD 458.3 million in 2025, and is projected to attain USD 655.1 million by 2032, reflecting a CAGR of 5.2% during the forecast period. North America dominated the market in 2024 with a 42.11% share, supported by its advanced healthcare infrastructure and high prevalence of chronic conditions requiring surgical intervention.

Recombinant thrombin, produced using recombinant DNA technology, offers improved safety compared to bovine or human-derived thrombin due to significantly lower risks of immunogenic reactions, viral transmission, and allergic responses. As biotechnology advances and healthcare facilities increasingly prioritize high-purity hemostatic solutions, recombinant thrombin continues to gain clinical importance across cardiovascular, neurology, orthopedic, liver, and general surgery specialties.

Market Dynamics

Drivers

Increasing Number of Surgical Procedures

A surge in chronic diseases-such as cardiovascular disorders, orthopedic impairments, and neurological conditions-has led to a high number of surgical interventions globally. Lifestyle risks such as tobacco use, stress, and physical inactivity further contribute to disease burden. This has driven healthcare facilities to adopt recombinant thrombin for precise intraoperative bleeding control.

For example, Germany recorded 168,841 heart surgery procedures in 2023, a 4.1% increase from 2022, showcasing the growing need for reliable hemostatic agents.

Restraints

High Cost of Recombinant Thrombin

The complex biotechnological manufacturing process significantly increases production costs, making recombinant thrombin more expensive than traditional thrombin products. For instance, Recothrom 20,000 IU costs approximately USD 377.23, limiting its adoption in low-income nations or underfunded healthcare systems. Additionally, limited reimbursement support further restricts market penetration despite its superior safety profile.

Opportunities

Adverse Effects of Human and Bovine Thrombin Create Market Potential

Traditional thrombin products such as bovine-derived THROMBIN-JMI have been associated with adverse events including immune reactions, bleeding complications, and thromboembolic events. Recombinant thrombin eliminates risks of pathogen transmission and significantly reduces antibody formation.

Since only one FDA-approved recombinant thrombin (Recothrom) exists, market players have substantial opportunity to explore new formulations and expand product pipelines.

Challenges

Complex Manufacturing Process

Producing recombinant thrombin requires precise gene cloning, controlled cell culture systems, and high-level purification techniques. Batch failures, strict compliance needs, and challenges in scalability raise operational costs and hinder rapid market expansion.

Market Trends

Growing Development of Combination Hemostatic Products

Leading companies are increasingly developing combination products to enhance intraoperative bleeding control.

In April 2023, Baxter launched Floseal + Recothrom, the world's first active flowable hemostat integrating recombinant thrombin, representing a major advancement in surgical hemostasis.

Segmentation Analysis

By Application

The therapeutic segment dominated in 2024, driven by extensive use in cardiovascular, neurosurgical, orthopedic, and liver surgeries. In the U.S. alone, over 1.0 million transcatheter cardiovascular procedures were performed in 2024, each requiring efficient bleeding control.

The research segment also held a significant share, as recombinant thrombin is widely used for fusion protein cleavage, molecular biology studies, and high-purity experimental applications.

By End User

Hospitals and ambulatory surgical centers (ASCs) led the market due to high surgical volumes. As an example, over 700,000 knee replacement surgeries were conducted in the U.S. in 2024.

Research institutes continue to expand usage due to the increasing adoption of recombinant proteins in biotechnology research.

Regional Outlook

North America (2024 Value: USD 185.2 Million)

The region dominates the market due to high surgical procedure rates, technological adoption, and strong awareness about safe hemostats. The U.S. leads with significant cardiovascular and orthopedic surgery volumes.

Europe

Europe represents the second-largest market driven by its aging population and growing trauma-related surgeries. Biotechnology R&D advancements in Germany, France, and the U.K. further support market expansion.

Asia Pacific

Expected to grow at the fastest rate due to expanding patient pools, increased surgical volumes, and rising research investments.

For instance, AstraZeneca invested USD 2.5 billion in 2025 to establish an R&D center in Beijing.

Latin America & Middle East/Africa

Growth is fueled by improving healthcare infrastructure and rising availability of minimally invasive surgical centers, such as Burjeel Holdings' one-day surgery centers launched in 2024.

Conclusion

Growing surgical needs, improved safety profiles, and rising biotechnological advancements are set to expand the recombinant thrombin market from USD 439.8 million in 2024 to USD 655.1 million by 2032. With increasing demand for efficient and safe hemostatic agents, the market is positioned for stable, long-term global growth.

Segmentation By Application

  • Therapeutic
  • Research

By End User

  • Hospitals and ASCs
  • Research Institutes
  • Others

By Region

  • North America (By Application, End User, and Country)
    • U.S.
    • Canada
  • Europe (By Application, End User, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Application, End User, and Country/Sub-region)
    • Japan
    • China
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Application, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Application, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Regolatory Scenarios, By Key Countries/Regions
  • 4.2. Technological Advancements in the Market
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 5.1. Market Analysis, Insights and Forecast - By Application
    • 5.1.1. Therapeutic
    • 5.1.2. Research
  • 5.2. Market Analysis, Insights and Forecast - By End User
    • 5.2.1. Hospitals & ASCs
    • 5.2.2. Specialty Clinics
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - Region
    • 5.3.1. North America
    • 5.3.2. Europe
    • 5.3.3. Asia Pacific
    • 5.3.4. Latin America
    • 5.3.5. Middle East & Africa

6. North America Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 6.1. Market Analysis, Insights and Forecast - By Application
    • 6.1.1. Therapeutic
    • 6.1.2. Research
  • 6.2. Market Analysis, Insights and Forecast - By End User
    • 6.2.1. Hospitals & ASCs
    • 6.2.2. Specialty Clinics
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Country
    • 6.3.1. S.
    • 6.3.2. Canada

7. Europe Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 7.1. Market Analysis, Insights and Forecast - By Application
    • 7.1.1. Therapeutic
    • 7.1.2. Research
  • 7.2. Market Analysis, Insights and Forecast - By End User
    • 7.2.1. Hospitals & ASCs
    • 7.2.2. Specialty Clinics
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.3.1. U.K.
    • 7.3.2. Germany
    • 7.3.3. France
    • 7.3.4. Italy
    • 7.3.5. Spain
    • 7.3.6. Scandinavia
    • 7.3.7. Rest of Europe

8. Asia Pacific Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 8.1. Market Analysis, Insights and Forecast - By Application
    • 8.1.1. Therapeutic
    • 8.1.2. Research
  • 8.2. Market Analysis, Insights and Forecast - By End User
    • 8.2.1. Hospitals & ASCs
    • 8.2.2. Specialty Clinics
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.3.1. China
    • 8.3.2. Japan
    • 8.3.3. India
    • 8.3.4. Southeast Asia
    • 8.3.5. Australia
    • 8.3.6. Rest of Asia Pacific

9. Latin America Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 9.1. Market Analysis, Insights and Forecast - By Application
    • 9.1.1. Therapeutic
    • 9.1.2. Research
  • 9.2. Market Analysis, Insights and Forecast - By End User
    • 9.2.1. Hospitals & ASCs
    • 9.2.2. Specialty Clinics
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.3.1. Brazil
    • 9.3.2. Mexico
    • 9.3.3. Rest of Latin America

10. Middle East & Africa Recombinant Thrombin Market Analysis, Insights and Forecast, 2019-2032

  • 10.1. Market Analysis, Insights and Forecast - By Application
    • 10.1.1. Therapeutic
    • 10.1.2. Research
  • 10.2. Market Analysis, Insights and Forecast - By End User
    • 10.2.1. Hospitals & ASCs
    • 10.2.2. Specialty Clinics
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.3.1. GCC
    • 10.3.2. South Africa
    • 10.3.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2024)
  • 11.2. Company Profiles
    • 11.2.1. Baxter
      • 11.2.1.1. Overview
      • 11.2.1.2. Product Types
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Merck KGaA
      • 11.2.2.1. Overview
      • 11.2.2.2. Product Types
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Bio-Techne
      • 11.2.3.1. Overview
      • 11.2.3.2. Product Types
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. AMSBIO
      • 11.2.4.1. Overview
      • 11.2.4.2. Product Types
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Enzyme Research Laboratories Ltd.
      • 11.2.5.1. Overview
      • 11.2.5.2. Product Types
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Proteintech Group, Inc
      • 11.2.6.1. Overview
      • 11.2.6.2. Product Types
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 2: Global Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 3: Global Recombinant Thrombin Market Revenue (USD million) Forecast, by Region, 2019-2032
  • Table 4: North America Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 5: North America Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 6: North America Recombinant Thrombin Market Revenue (USD million) Forecast, By Country, 2019-2032
  • Table 7: Europe Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 8: Europe Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 9: Europe Recombinant Thrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 10: Asia Pacific Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 11: Asia Pacific Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 12: Asia Pacific Recombinant Thrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 13: Latin America Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 14: Latin America Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 15: Latin America Recombinant Thrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032
  • Table 16: Middle East & Africa Recombinant Thrombin Market Revenue (USD million) Forecast, by Application, 2019-2032
  • Table 17: Middle East & Africa Recombinant Thrombin Market Revenue (USD million) Forecast, by End User, 2019-2032
  • Table 18: Middle East & Africa Recombinant Thrombin Market Revenue (USD million) Forecast, By Country/ Sub-region, 2019-2032

List of Figures

  • Figure 1: Global Recombinant Thrombin Market Revenue Breakdown (USD million, %) by Region, 2024 & 2032
  • Figure 2: Global Recombinant Thrombin Market Value Share (%), by Application, 2024 & 2032
  • Figure 3: Global Recombinant Thrombin Market Value Share (%), by End User, 2024 & 2032
  • Figure 4: Global Recombinant Thrombin Market Value Share (%), by Region, 2024 & 2032
  • Figure 5: North America Recombinant Thrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 6: North America Recombinant Thrombin Market Value Share (%), by Application, 2024
  • Figure 7: North America Recombinant Thrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 8: North America Recombinant Thrombin Market Value Share (%), by End User, 2024
  • Figure 9: North America Recombinant Thrombin Market Value (USD million), By Country, 2024 & 2032
  • Figure 10: North America Recombinant Thrombin Market Value Share (%), By Country, 2024
  • Figure 11: Europe Recombinant Thrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 12: Europe Recombinant Thrombin Market Value Share (%), by Application, 2024
  • Figure 13: Europe Recombinant Thrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 14: Europe Recombinant Thrombin Market Value Share (%), by End User, 2024
  • Figure 15: Europe Recombinant Thrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 16: Europe Recombinant Thrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 17: Asia Pacific Recombinant Thrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 18: Asia Pacific Recombinant Thrombin Market Value Share (%), by Application, 2024
  • Figure 19: Asia Pacific Recombinant Thrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 20: Asia Pacific Recombinant Thrombin Market Value Share (%), by End User, 2024
  • Figure 21: Asia Pacific Recombinant Thrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 22: Asia Pacific Recombinant Thrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 23: Latin America Recombinant Thrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 24: Latin America Recombinant Thrombin Market Value Share (%), by Application, 2024
  • Figure 25: Latin America Recombinant Thrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 26: Latin America Recombinant Thrombin Market Value Share (%), by End User, 2024
  • Figure 27: Latin America Recombinant Thrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 28: Latin America Recombinant Thrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 29: Middle East & Africa Recombinant Thrombin Market Value (USD million), by Application, 2024 & 2032
  • Figure 30: Middle East & Africa Recombinant Thrombin Market Value Share (%), by Application, 2024
  • Figure 31: Middle East & Africa Recombinant Thrombin Market Value (USD million), by End User, 2024 & 2032
  • Figure 32: Middle East & Africa Recombinant Thrombin Market Value Share (%), by End User, 2024
  • Figure 33: Middle East & Africa Recombinant Thrombin Market Value (USD million), By Country/ Sub-region, 2024 & 2032
  • Figure 34: Middle East & Africa Recombinant Thrombin Market Value Share (%), By Country/ Sub-region, 2024
  • Figure 35: Global Recombinant Thrombin Market Share (%), By Company, 2024